#United States #Cranbury #Berger Montague #Rocket Pharmaceuticals #RCKT

Rocket Pharmaceuticals Faces Legal Action Over Safety Disclosure Issues

In a recent announcement, Berger Montague PC, a prominent law firm based in Philadelphia, revealed that it is looking into a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This case is currently in motion in the U.S. District Court for the District of New Jersey and has raised alarms among investors regarding the company’s safety disclosures related to its RP-A501 gene therapy program.

Rocket Pharmaceuticals, which is located in Cranbury, New Jersey, is a biotechnology firm dedicated to developing innovative gene therapies for rare diseases. However, the lawsuit claims that the company did not adequately inform investors about a significant protocol modification, notably the inclusion of a new immunomodulatory agent prior to a serious adverse event that led to an FDA clinical hold.

The Allegations

The crux of the allegations revolves around a patient death that occurred during clinical trials of the RP-A501 gene therapy. Following this tragic incident, Rocket Pharmaceuticals disclosed the details, which prompted a dramatic drop in its stock price. The share value plummeted nearly 37% in a very short period, declining from $6.27 on May 23, 2025, to $2.33 by May 27, 2025.

According to the lawsuit, such alarming alterations in the trial's protocol were not communicated to investors before the serious adverse event took place, implying that crucial information was withheld, which could have influenced investor decisions.

Investor Implications

Investors who acquired Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025, termed as the 'Class Period,' may be eligible to recover losses experienced as a result of this alleged misconduct. The deadline set for potentially becoming a lead plaintiff in this class action suit is August 11, 2025. Interested parties are encouraged to reach out to Berger Montague for more information about their rights and the lawsuit’s ongoing developments.

About Berger Montague

Founded in 1970, Berger Montague has established a solid reputation as a leading firm in securities class action litigation. With offices spread across multiple cities in the United States, including Philadelphia, Minneapolis, and San Francisco, the firm has effectively represented both institutional and individual investors in their pursuit of justice. Their extensive experience in securities litigation makes them a key player in currently investigating the claims against Rocket Pharmaceuticals.

As news surrounding this lawsuit unfolds, investors will be paying close attention to the developments regarding Rocket Pharmaceuticals and its RP-A501 gene therapy program. The outcome of this case may have significant repercussions not only for the company’s stock value but also for broader investor confidence in the biotechnology sector.

For further inquiries or to discuss potential claims, affected investors can contact Senior Counsel Andrew Abramowitz or Caitlin Adorni at Berger Montague. This lawsuit not only underscores the critical importance of transparency in the pharmaceutical companies but is also a reminder of the potential risks involved for investors navigating the biotechnology landscape.

Stay informed as we continue to track the developments surrounding this significant legal action.